Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

被引：4
|
作者：
John, Nevin [1 ]
Carroll, Antonia [2 ]
Brownlee, Wallace J. [2 ,3 ]
Chataway, Jeremy [1 ,2 ]
机构：
[1] UCL, Inst Neurol, Neuroinflammat, London WC1N 3BG, England
[2] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England
[3] Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, London, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
FINGOLIMOD;
D O I：
10.1136/jnnp-2019-320687
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1376 / +
页数：3
相关论文
共 50 条
  • [1] Alemtuzumab for patients with relapsing multiple sclerosis after Natalizumab
    Pena Martinez, J.
    Lopez Real, A. M.
    Oterino Duran, A.
    Costa Arpin, E.
    Gonzalez Suarez, I.
    Fernandez Fernandez, E.
    Rodriguez Regal, A.
    Solar Sanchez, D. M.
    Garcia Estevez, D. A.
    Rodriguez Rodriguez, M.
    Lorenzo Gonzalez, J. R.
    Prieto Gonzalez, J. M.
    Fernandez Uria, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 306 - 306
  • [2] Switching from fingolimod to alemtuzumab in patients with active relapsing multiple sclerosis
    Carroll, A.
    Shields, A.
    Brownlee, W. J.
    Chataway, J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 875 - 876
  • [3] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [4] Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis
    Fakih, Ali Ussama
    Sahraian, Mohammad Ali
    Paybast, Sepideh
    Moghadasi, Abdorreza Naser
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [5] Switching from natalizumab to ocrelizumab in patients with multiple sclerosis
    Levin, Seth N.
    Ezuma, Chimere
    Levine, Libby
    Vargas, Wendy S.
    Farber, Rebecca S.
    De Jager, Philip L.
    Riley, Claire S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (14) : 1964 - 1965
  • [6] Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
    Prosperini, Luca
    Gianni, Costanza
    Leonardi, Laura
    De Giglio, Laura
    Borriello, Giovanna
    Galgani, Simonetta
    Pozzilli, Carlo
    Gasperini, Claudio
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (01) : 64 - 71
  • [7] Natalizumab for relapsing multiple sclerosis
    Tenser, RB
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2387 - 2387
  • [8] Shifting from natalizumab to alemtuzumab in pediatriconset multiple sclerosis
    Gaggiola, M.
    Rinaldi, F.
    Mauceri, V. A.
    De Napoli, F.
    Scialpi, G.
    Franciotta, S.
    Miscioscia, A.
    Zanotelli, G.
    Perini, P.
    Gallo, P.
    Puthenparampil, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 921 - 922
  • [9] Clinical Outcomes of 200 Multiple Sclerosis Patients Switching from Natalizumab to Alemtuzumab in a Single United States MS Center
    LaGanke, Christopher
    Adcock, Amanda
    NEUROLOGY, 2016, 86
  • [10] Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis:. case series
    Notas, Konstantinos
    Papadaki, Efrosini
    Orologas, Anastasios
    Moschou, Maria
    Kimiskidis, Vasilios K.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 38
12345